[Evaluation of the antiviral therapy for chronic hepatitis C in patients unresponsive to previous treatment with regard to the interleukin-28B genotypes].

The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin. In addition to the implementation of the antiviral activity of IFN-α, interleukin-1ß (IL-1ß) and interferon-gamma (IFN-γ) are involved. The goal of this work was to evaluate the efficacy of the HCV therapy with cytokines in patients unresponsive to previous therapy with unfavorable genotypes of IL-28B gene. SVR was achieved in 44.4% of patients with an unfavorable IL-28B genetic background with biochemical response without serious adverse effects or unexpected adverse effects, thereby corroborating the inclusion of proven safety Betaleukin® and Ingaron in the schemes of the antiviral therapy in combination with standard interferon-α and ribavirin in patients with recurrent HCV-infection.

[Applying of recombinant interleukin-1ß to treat chronic hepatitis C for patients non-response to the previous antiviral therapy].

UNLABELLED: The search for rational treatment of CHC patients, non-response to the primary antiviral therapy especially with unfavorable genotypes for interleukin-28B, remains valid. PURPOSE: To evaluate the efficacy and safety of recombinant IL-1ß (Betaleukin) in combined antiviral therapy in patients with chronic hepatitis C who did not respond to previous treatment. The study included 26 patients with HCV-1. Patients were divided into 2 groups depending on retreatment scheme: group 1 (n = 10) was treated with recombinant IFN-a2b ("Interal"-P) 5 million IU daily subcutaneously for 12 weeks then every other day until the end of treatment; ribavirin, depending on body weight (800-1200 mg/day) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day for 12 weeks (45 injections); group 2 (n = 16)--recombinant IFN-a2b ("Interal"-P) 3 million IU every other day subcutaneously for 48 weeks; ribavirin--1000 mg/day (for a body weight < 75 kg), 1200 mg/day (for a body weight > 75 kg) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day, five courses for 3 weeks (50 injections). RESULTS: Combined antiviral therapy (α-IFN2b and RIB) with IL-1ß (Betaleukin) in patients who had not responded to previous therapy, with a predominance of unfavorable genetic background for IL-28B typing helped to improve SVR (44%) with more efficient 45-day administration of the medications in the first 12 weeks in combination with inductive α-IFN therapy and achieve biochemical response at week 24 of treatment. Adverse effects of the IL-1ß mainly limited with fever, moderate local reactions and do not require discontinuation of treatment.

[Pegylated intereferon hematological safety in comparison with standard].

Comparative analysis of adverse hematologic effects in 135 patients with with chronic hepatits C on combined antiviral therapy of pegylated and "short lived" forms of alpha-interferon in combination with ribavirin was investigated. As a result of the comparison, the response to antiviral therapy in patients with chronic hepatitis C treated with daily administration of simple interferon-alpha in hematologic data is similar in patients undergoing treatment with pegylated drugs.

[Intestinal microflora and concomitant gastrointestinal diseases in patients with chronic hepatitis B and C]. / Kishechnaia mikroflora i soputstvuiushchie zabolevaniia zheludochno-kishechnogo trakta u bol'nykh khronicheskimi virusnymi gepatitami B and C.

In chronic viral hepatitis B and C the development of intestinal dysbacteriosis and high occurrence of concomitant diseases of the gastrointestinal tract were observed. In cases of increased dysbacteriosis degree and in the presence of concomitant diseases the blood plasma of patients exhibited higher activity in reaction with the of amebocytes lysate obtained from crabs of the genus Limulus. A suggestion was made that the endotoxin of Gram negative intestinal microflora could probably play some role in the development of pathological processes in chronic viral hepatitis B and C.

[Functional activity of endotoxin binding factors in chronic viral hepatitis B and C]. / Funktsional'naia aktivnost' faktorov, sviazyvaiushchikh éndotoksin, pri khronicheskikh virusnykh gepatitakh B i C..

The functional state of cell-mediated and humoral antiendotoxin factors in patients with chronic viral hepatitides B and C has been studied. A decreased content of antibodies to glycolipid of chemotype Re and to Escherichia coli O14 with common enterobacterial antigen was shown to occur in these diseases. In addition, a decreased number of neutrophils, eosinophils and thrombocytes has been noted. The conclusion has been made that patients with chronic hepatitides are not protected from the pathogenic action of endotoxin penetrating from the intestines into the systemic blood stream.